1. Home
  2. TVTX vs UWMC Comparison

TVTX vs UWMC Comparison

Compare TVTX & UWMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
  • UWMC
  • Stock Information
  • Founded
  • TVTX 2008
  • UWMC 1986
  • Country
  • TVTX United States
  • UWMC United States
  • Employees
  • TVTX N/A
  • UWMC N/A
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • UWMC Finance: Consumer Services
  • Sector
  • TVTX Health Care
  • UWMC Finance
  • Exchange
  • TVTX Nasdaq
  • UWMC Nasdaq
  • Market Cap
  • TVTX 1.5B
  • UWMC 1.4B
  • IPO Year
  • TVTX N/A
  • UWMC N/A
  • Fundamental
  • Price
  • TVTX $23.36
  • UWMC $6.90
  • Analyst Decision
  • TVTX Strong Buy
  • UWMC Hold
  • Analyst Count
  • TVTX 16
  • UWMC 7
  • Target Price
  • TVTX $35.07
  • UWMC $5.54
  • AVG Volume (30 Days)
  • TVTX 2.6M
  • UWMC 8.9M
  • Earning Date
  • TVTX 10-30-2025
  • UWMC 11-06-2025
  • Dividend Yield
  • TVTX N/A
  • UWMC 5.79%
  • EPS Growth
  • TVTX N/A
  • UWMC 112.84
  • EPS
  • TVTX N/A
  • UWMC 0.07
  • Revenue
  • TVTX $333,865,000.00
  • UWMC $2,622,828,000.00
  • Revenue This Year
  • TVTX $83.26
  • UWMC $25.96
  • Revenue Next Year
  • TVTX $43.19
  • UWMC N/A
  • P/E Ratio
  • TVTX N/A
  • UWMC $104.25
  • Revenue Growth
  • TVTX 87.94
  • UWMC 13.45
  • 52 Week Low
  • TVTX $11.89
  • UWMC $3.80
  • 52 Week High
  • TVTX $28.69
  • UWMC $9.25
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 64.87
  • UWMC 78.10
  • Support Level
  • TVTX $20.84
  • UWMC $5.50
  • Resistance Level
  • TVTX $28.69
  • UWMC $7.14
  • Average True Range (ATR)
  • TVTX 1.44
  • UWMC 0.22
  • MACD
  • TVTX 0.62
  • UWMC 0.09
  • Stochastic Oscillator
  • TVTX 56.60
  • UWMC 85.84

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

About UWMC UWM Holdings Corporation

UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.

Share on Social Networks: